[go: up one dir, main page]

WO2008068765A3 - Compositions and methods for inhibiting hiv-1 replication and integrase activity - Google Patents

Compositions and methods for inhibiting hiv-1 replication and integrase activity Download PDF

Info

Publication number
WO2008068765A3
WO2008068765A3 PCT/IL2007/001516 IL2007001516W WO2008068765A3 WO 2008068765 A3 WO2008068765 A3 WO 2008068765A3 IL 2007001516 W IL2007001516 W IL 2007001516W WO 2008068765 A3 WO2008068765 A3 WO 2008068765A3
Authority
WO
WIPO (PCT)
Prior art keywords
replication
hiv
compositions
methods
inhibiting hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2007/001516
Other languages
French (fr)
Other versions
WO2008068765A2 (en
Inventor
Assaf Friedler
Abraham Loyter
Moshe Kotler
Amnon Hizi
Zvi Hayouka
Joseph Rosenbluh
Aviad Levin
Shoshana Loya
Elena Britan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Ramot at Tel Aviv University Ltd
Publication of WO2008068765A2 publication Critical patent/WO2008068765A2/en
Publication of WO2008068765A3 publication Critical patent/WO2008068765A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides isolated peptides comprising a fragment of an HIV-1 Rev protein and use of same for treating HIV-1 infection, inhibiting HIV-1 replication and inhibiting DNA binding and 3 '-end processing activity of HIV-1 integrase protein.
PCT/IL2007/001516 2006-12-07 2007-12-09 Compositions and methods for inhibiting hiv-1 replication and integrase activity Ceased WO2008068765A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87325106P 2006-12-07 2006-12-07
US60/873,251 2006-12-07

Publications (2)

Publication Number Publication Date
WO2008068765A2 WO2008068765A2 (en) 2008-06-12
WO2008068765A3 true WO2008068765A3 (en) 2008-12-11

Family

ID=39492728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/001516 Ceased WO2008068765A2 (en) 2006-12-07 2007-12-09 Compositions and methods for inhibiting hiv-1 replication and integrase activity

Country Status (1)

Country Link
WO (1) WO2008068765A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2574988T3 (en) 2008-10-06 2016-06-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. Peptides derived from HIV-1 integrase stimulants that interfere with the Rev-integrase protein
JP2012521193A (en) * 2009-03-19 2012-09-13 インテグラテック プロテオミクス， エルエルシー Viral integrase inhibitors and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US20060089488A1 (en) * 2004-07-30 2006-04-27 Toagosei Co., Ltd. Antimicrobial peptides and use thereof
WO2007028219A1 (en) * 2005-09-05 2007-03-15 Fundacão De Amparo À Pesquisa Do Estado De São Paulo Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US20060089488A1 (en) * 2004-07-30 2006-04-27 Toagosei Co., Ltd. Antimicrobial peptides and use thereof
WO2007028219A1 (en) * 2005-09-05 2007-03-15 Fundacão De Amparo À Pesquisa Do Estado De São Paulo Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GLEENBERG I O ET AL: "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase", JOURNAL OF BIOLOGICAL CHEMISTRY 20050610 US, vol. 280, no. 23, 10 June 2005 (2005-06-10), pages 21987 - 21996, XP002487932, ISSN: 0021-9258 *
ROSENBLUH J ET AL: "Interaction between HIV-1 Rev and integrase proteins: A basis for the development of anti-HIV peptides", JOURNAL OF BIOLOGICAL CHEMISTRY 20070525 US, vol. 282, no. 21, 25 May 2007 (2007-05-25), pages 15743 - 15753, XP002487933, ISSN: 0021-9258 1083-351X *

Also Published As

Publication number Publication date
WO2008068765A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
EP2537524A3 (en) Treatment of T-cell mediated diseases
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
WO2005115398A3 (en) Hiv integrase inhibitors
WO2004014312A3 (en) Small-mer compositions and methods of use
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2007044565A3 (en) Composition and synthesis of new reagents for inhibition of hiv replication
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2008142303A3 (en) Use of an anti-cxcr4 antibody for treating cancer
WO2009020559A3 (en) Agents that inhibit p-tefb interactions and methods of use thereof
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2008049990A3 (en) Use of an anti-cd151 antibody in the treatment of cancer
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2008051448A3 (en) Methods and compositions for efficient removal of protein a from binding molecule preparations
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2008068765A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2007143548A3 (en) Myxoma virus mutants for cancer treatment
WO2007000770A3 (en) Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
WO2005070042A8 (en) Novel chemical compounds
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827480

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827480

Country of ref document: EP

Kind code of ref document: A2